Atossa Therapeutics Inc (ATOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -11,457 | -4,786 | -20,606 | -15,774 | -10,577 |
| Depreciation Amortization | 4 | 2 | 23 | 21 | 15 |
| Accounts payable and accrued liabilities | 335 | -121 | 128 | -921 | -1,051 |
| Other Working Capital | -2,952 | -1,900 | -1,156 | -702 | -1,037 |
| Other Operating Activity | 3,243 | 1,927 | 5,139 | 4,569 | 2,905 |
| Operating Cash Flow | $-10,827 | $-4,878 | $-16,472 | $-12,807 | $-9,745 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -13 | -13 | -9 | -9 | N/A |
| Investing Cash Flow | $-13 | $-13 | $-9 | $-9 | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | N/A | 113,877 | 113,877 | 112,624 |
| Other Financing Activity | 0 | 0 | -573 | -574 | 0 |
| Financing Cash Flow | $N/A | $N/A | $113,304 | $113,303 | $112,624 |
| Beginning Cash Position | 136,487 | 136,487 | 39,664 | 39,664 | 39,664 |
| End Cash Position | 125,647 | 131,596 | 136,487 | 140,151 | 142,543 |
| Net Cash Flow | $-10,840 | $-4,891 | $96,823 | $100,487 | $102,879 |
| Free Cash Flow | |||||
| Operating Cash Flow | -10,827 | -4,878 | -16,472 | -12,807 | -9,745 |
| Capital Expenditure | -13 | -13 | -9 | -9 | N/A |
| Free Cash Flow | -10,840 | -4,891 | -16,481 | -12,816 | -9,745 |